The Guildford, England-based liquid biopsy company said the study undertaken by the National & Kapodistrian University of Athens used the Parsortix system to isolate and harvest circulating tumour ...
Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure approval for treating locally advanced or metastatic non-small cell lung ...
Researchers from Australia and Germany have for the first time cured patients suffering from toxic epidermal necrolysis (TEN) ...
mice with hair follicle-specific deletion of epidermal growth factor receptor (EGFR ΔEgr2) acquire a phenotype of chronic folliculitis (inflammation around the follicle) that is associated with hair ...
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of ...
Basal cell carcinoma (BCC) is a heterogeneous malignant neoplasm and can cause great morbidity as most occur in highly visible areas ...
More than paying lip service, the cells may offer new opportunities to research and treat various lip conditions ...
Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...
We've made massive strides against the deadly disease, but rates haven't fallen for people diagnosed with the disease who've never smoked.
A team has developed a large-scale drug screening technique that can track target molecule behavior within cells. The researchers verified their technique by testing the epidermal growth factor ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for ...
Formation of the skin barrier requires rapid proliferation coupled with differentiation and stratification of the embryonic epidermis. Basal progenitors give rise to progeny throughout development – ...